Relief For Migraine as England’s NICE Reverses Ajovy Knockback
Executive Summary
The latest decision by the health technology assessment body means up to 10,000 people will be able to receive Teva’s drug on the National Health Service. Ajovy is the first anti-CGRP migraine therapy recommended by NICE, whose decision will also be of interest to CGRP inhibitor rivals including Novartis, Lilly and Lundbeck.